NEW YORK, NY / ACCESSWIRE / October 4, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
KRBP Shareholders Click Here: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=32416&wire=1
NIO Shareholders Click Here: https://www.zlk.com/pslra-1/nio-inc-class-action-submission-form?prid=32416&wire=1
TSP Shareholders Click Here: https://www.zlk.com/pslra-1/tusimple-lawsuit-loss-submission-form?prid=32416&wire=1
* ADDITIONAL INFORMATION BELOW *
Kiromic BioPharma, Inc. (NASDAQ:KRBP)
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : October 4, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=32416&wire=1
The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the 'Offering Documents') failed to disclose that the Food and Drug Administration ('FDA') had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ('IND') applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.
NIO Inc. (NYSE:NIO)
NIO Lawsuit on behalf of: investors who purchased August 20, 2020 - July 11, 2022
Lead Plaintiff Deadline : October 24, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nio-inc-class-action-submission-form?prid=32416&wire=1
According to the filed complaint, during the class period, NIO Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) NIO pulled forward revenue by selling batteries to a related party, which owned the batteries and managed users' subscriptions; (2) through the related party, NIO also recognized enormous depreciation savings; (3) as a result of the foregoing, the Company's revenue and net loss were overstated; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
TuSimple Holdings Inc. (NASDAQ:TSP)
This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple common stock pursuant and/or traceable to documents issued in connection with TuSimple's April 15, 2021 initial public offering; and/or (b) that purchased or otherwise acquired TuSimple securities between April 15, 2021 and August 1, 2022, both dates inclusive.
Lead Plaintiff Deadline : October 31, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tusimple-lawsuit-loss-submission-form?prid=32416&wire=1
According to the filed complaint, (i) TuSimple's commitment to safety was significantly overstated and defendants concealed fundamental problems with the Company's technology; (ii) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors; (iii) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favor of unrealistically ambitious testing and delivery schedules; (iv) the aforementioned conduct made accidents involving the Company's autonomous driving technology more likely; (v) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward the Company; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: